Evidence map›Paper›PMID 32961531›Full record

Trial reportInternational archives of allergy and immunology

Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study.

Davide Caimmi, Catherine Neukirch, Renaud Louis, Olivier Malard, Gabriel Thabut, Pascal Demoly

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in International archives of allergy and immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Intranasal essential oils in therapy: advances in clinical applications and delivery mechanisms.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Davide CaimmiDepartment of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France, davide.caimmi@gmail.com.
Catherine NeukirchDepartments of Pneumology A and B and INSERM U1152, Bichat-Claude Bernard University Hospital, Paris, France.
Renaud LouisDepartment of Pulmonary Medicine, CHU Sart-Tilman, IGIGA Research Group, University of Liege, Liège, Belgium.
Olivier MalardService d'ORL et de Chirurgie Cervico-Faciale, University Hospital of Nantes, Hôtel Dieu, Nantes, France.
Gabriel ThabutDepartments of Pneumology A and B and INSERM U1152, Bichat-Claude Bernard University Hospital, Paris, France.
Pascal DemolyDepartment of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France.
Inserm · FRUniversité Claude Bernard Lyon 1 · FRHotel Dieu Hospital · CAUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAmong allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms.

methodsThis prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel® Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed.

resultsThe mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 4.1 (p < 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p < 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 18.5 L/min.

conclusionA hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.

Indexed as

AdultAnti-Allergic AgentsFemaleHumansMaleMiddle AgedNasal SpraysOils, VolatileProspective StudiesRhinitis, Allergic, PerennialSymptom AssessmentTreatment OutcomeYoung AdultAnti-Allergic AgentsNasal SpraysOils, VolatileAllergic rhinitisControlEssential oilsManagement

Identifiers

PMID32961531
PMCPMC7949223
OpenAlexW3088460605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.